amgen glp-1 obesity drug market potential 2025 Anti-obesity Drugs Growth Trend Analysis GLP-1 Market Trends and Global

It comes in a single-use self-injectable pen that you take once per week

Previous studies have found that ceasing use of GLP-1 agonists results in patients regaining some or all of the weight they'd lost while taking the medication

Glucagon suppression (reduces glucose production in the liver)

Decreasing neck and abdominal adiposity directly reduces mechanical airway resistance, a key factor in OSAS pathogenesis (38, 49)

It is reasonable to expect that maridebart cafraglutide, if approved, would be subject to a similar NICE appraisal process to determine its place in UK obesity management

FDA-approved for type 2 diabetes and for reducing the risk of major adverse cardiovascular events in certain adults with type 2 diabetes and established cardiovascular disease